

FORM CODE: PHF Version: A 06/05/07 ARIC ID: <NNNNNN> CY: < 00 > SEQ: <00>

O.M.B 0925-0281 Exp. XX/XXXX

| Dear < Dr >,  |   |
|---|---|
| Your patient, < Ms/Mr. > who is a long time participant in the ARIC Study, has indicated to ARIC study personnel that < s/he > has been diagnosed with heart failure. We have your patient's authorization to ask you to provide this information for our study records. We appreciate your response to the following questions and request that you return this form in the enclosed envelope at your earliest convenience (ideally within 2 weeks). |   |
| Thank you.  |   |
| Sincerely, < Field center medical director >  | Date < Date letter is sent >  |
| Patient Name < Ms/Mr. >   | Patient Date of Birth < mm/dd/yyyy >  |
| Has this patient ever had heart failure or cardiomyop   | oathy of any type? ☐ Yes ☐ Unsure ☐ No ——————————————————————————————————   |
| 2. If the patient has or ever had heart failure or cardiom  (a) Is this patient's condition characterized as predo  □ Systolic dysfunction □ Diastolic dysfuncti  (b) Estimated LVEF (worst):%  (b.1.) If LVEF is not specifically available, estir  □ Normal □ Decreased mildly □ D  (c) Estimated date of onset or diagnosis:/  | minantly: on  |
| 3. Has this patient ever had (check all that apply):  | •   |
| <ul> <li>□ Atrial fibrillation on an ECG?</li> <li>□ Pulmonary rales on a physical examination?</li> <li>□ Rhonchi on a physical examination?</li> <li>4. Was s/he prescribed treatment specifically for heart</li> <li>□ Yes</li> <li>□ No</li> <li>□ Not known</li> </ul>   | <ul> <li>☐ Angina pectoris?</li> <li>☐ Previous MI?</li> <li>☐ Other coronary heart disease?</li> <li>☐ None of the above</li> <li>failure during the past year?</li> </ul> |
| 5. Was this patient prescribed any of the following during the past year? (check all that apply)  |   |
| ☐ ACE inhibitors ☐ Alpha blockers ☐ Aldosterone blocker ☐ Amiodarone / Antiarrhythmics ☐ Angiotensin II receptor blockers ☐ Anticoagulants ☐ Aspirin / Antiplatelets  | □ Beta blockers □ Calcium channel blockers □ Digitalis □ Diuretics □ Hydralazine □ Lipid-lowering agents □ Nitrates □ Other antihypertensives                               |
| Form completed by:  | Date:   |
| (Signature or stamp )   | (MM/ DD /YY)  |



O.M.B 0925-0281 Exp. 05/31/2010

Public reporting burden for this collection of information is estimated to average <u>4</u> minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0281). Do not return the completed form to this address.